Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
Not yet recruitingCTIS2025-523630-59-00
HepaRegeniX GmbHcolon carcinoma metastases
Target: 19Updated: 2026-04-20